At the immune signaling level, TNFα has been observed to induce the upregulation of secondary immune checkpoints, including TIM3 and PD-L1, within cancer cells, consequently diminishing the efficacy of anti-PD1 therapy. This evidence concerns the gene PDCD1 and cancer.